Eosinophilic Pneumonia, Acute vs Chronic

Diagnosis and management of the idiopathic eosinophilic pneumonias, distinguishing acute eosinophilic pneumonia (AEP, a corticosteroid-responsive cause of acute hypoxemic respiratory failure, often in new/relapsed smokers) from chronic eosinophilic pneumonia (CEP, a relapsing subacute illness with peripheral infiltrates and asthma), and from secondary causes (drugs, ABPA, EGPA, parasites). Routes by tempo and cause, covering BAL eosinophilia, corticosteroid response, and relapse risk.

Evidence tier: Expert consensus. Reflects expert-consensus criteria, not a prospectively validated instrument. Apply clinical judgment and local policy.

Decision points

  • Acute (days) or chronic (weeks–months) onset?
  • Idiopathic chronic EP, or a secondary cause?

Do-not-miss pitfalls

  • Peripheral blood eosinophilia is frequently ABSENT in acute eosinophilic pneumonia at presentation, do not exclude AEP because the blood eosinophil count is normal. BAL eosinophilia (≥25%) is the key diagnostic finding.
  • AEP is strongly linked to a recent change in inhalational exposure, new-onset smoking, smoking relapse, vaping/e-cigarettes, or dust. Always take a detailed recent-exposure history; removing the trigger prevents recurrence.
  • AEP can present as ARDS-like acute hypoxemic respiratory failure and is treatable, consider it and send BAL before attributing respiratory failure solely to infection or idiopathic ARDS.
  • Chronic eosinophilic pneumonia characteristically relapses on steroid taper, counsel patients and plan for prolonged low-dose maintenance rather than a short course. Abrupt cessation predicts relapse.
  • The "photographic negative of pulmonary edema" (peripheral, upper-lobe predominant infiltrates) is classic for CEP but present in only a minority, its absence does not exclude CEP.
  • Always exclude secondary causes before labeling idiopathic EP, drugs (nitrofurantoin, daptomycin, NSAIDs), ABPA, EGPA, and parasites each have specific management that differs from idiopathic disease.
  • Exclude Strongyloides (and treat empirically in at-risk patients) before giving corticosteroids for eosinophilic lung disease, steroids can precipitate fatal hyperinfection.
  • CEP is closely associated with asthma and frequently precedes or coexists with EGPA, new vasculitic, cardiac, neuropathic, or ANCA features warrant re-evaluation for EGPA.

Evidence & citations

  1. Suzuki Y, Suda T. Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019;68(4):413-419. PMID 31253537
  2. De Giacomi F, Vassallo R, Yi ES, Ryu JH. Acute eosinophilic pneumonia. Causes, diagnosis, and management. Am J Respir Crit Care Med. 2018;197(6):728-736. PMID 29206477
  3. Marchand E, Reynaud-Gaubert M, Lauque D, et al. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. Medicine (Baltimore). 1998;77(5):299-312. PMID 9772920
  4. Cottin V. Eosinophilic lung diseases. Immunol Allergy Clin North Am. 2023;43(2):289-322. PMID 37055090

Clinician decision support. Verify against the cited source. Not a substitute for clinical judgment. 100% on-device; no patient data is stored or transmitted.